Millendo Therapeutics (NASDAQ:MLND) Downgraded to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a sell rating in a research report released on Wednesday morning, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

MLND has been the topic of several other reports. ValuEngine cut shares of Welbilt from a hold rating to a sell rating in a research note on Wednesday, June 12th. Jefferies Financial Group started coverage on shares of Millendo Therapeutics in a research note on Wednesday, March 13th. They set a buy rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $23.25.

Millendo Therapeutics stock traded down $0.74 during trading hours on Wednesday, hitting $11.08. 72,100 shares of the stock were exchanged, compared to its average volume of 39,002. The company has a quick ratio of 7.83, a current ratio of 7.83 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $167.99 million, a PE ratio of -0.63 and a beta of 2.62. Millendo Therapeutics has a 12 month low of $6.77 and a 12 month high of $17.34. The stock has a 50-day moving average of $13.47.

Millendo Therapeutics (NASDAQ:MLND) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). As a group, sell-side analysts expect that Millendo Therapeutics will post -3.25 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Millendo Therapeutics during the 4th quarter worth about $203,000. Geode Capital Management LLC acquired a new position in shares of Millendo Therapeutics during the 4th quarter worth about $113,000. Worth Venture Partners LLC acquired a new position in shares of Millendo Therapeutics during the 4th quarter worth about $206,000. Great Point Partners LLC acquired a new position in shares of Millendo Therapeutics during the 4th quarter worth about $10,240,000. Finally, Tibra Equities Europe Ltd acquired a new position in shares of Millendo Therapeutics during the 1st quarter worth about $303,000. 44.07% of the stock is currently owned by institutional investors and hedge funds.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.